Role of ANG II in hypertension produced by chronic inhibition of nitric oxide synthase in conscious rats

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 271, Issue 2 40-2, 1996, Pages

  Melaragno, Matthew G ^a   Fink, Gregory D ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

blood pressure; N( ) nitro L arginine methyl ester; renin angiotensin system

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; LOSARTAN; N(G) NITRO DEXTRO ARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE;

ANIMAL MODEL; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; ENZYME INHIBITION; HYPERTENSION; MALE; NONHUMAN; PATHOPHYSIOLOGY; PRESSOR RESPONSE; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 33750705660     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.1996.271.2.h806     Document Type: Article

References (32)

1. Arnal, J. F., A. I. El Amrani, G. Chattelier, J. Ménard, and J. B. Michel. Cardiac weight in hypertension induced by nitric oxide synthase blockade. Hypertension Dallas 22: 380-387, 1993.
2. Baylis, C., K. Engels, L. Samsell, and P. Harton. Renal effects of acute endothelial-derived relaxing factor blockade are not mediated by angiotensin II. Am. J. Physiol. 264 (Renal Fluid Electrolyte Physiol. 33): F74-F78, 1993.
3. Bengis, R. G., T. G. Coleman, D. B. Young, and R. E. McCaa. Long-term blockade of angiotensin formation in various normotensive and hypertensive rat models using converting enzyme inhibitor (SQ 14,225). Circ. Res. 43, Suppl. I: I45-I53, 1978.
4. Brown, A. J., J. Casals-Stenzel, S. Gofford, A. F. Lever, and J. J. Morton. Comparison of fast and slow pressor effects of angiotensin II in the conscious rat. Am. J. Physiol. 241 (Heart Circ. Physiol. 10): H381-H388, 1981.
5. Campbell, D. J., A. Kladis, and A.-M. Duncan. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension Dallas 23: 439-449, 1994.
6. Cowley, A. W., and J. W. DeClue. Quantification of baroreceptor influence on arterial pressure changes seen in primary angiotensin-induced hypertension in dogs. Circ. Res. 39: 779-787, 1976.
7. Cunha, R. S., A. M. Cabral, and E. C. Vasquez. Evidence that the autonomie nervous system plays a major role in the L-NAME-induced hypertension in conscious rats. Am. J. Hypertens. 6: 806-809, 1993.
8. Dananberg, J., R. S. Sider, and R. J. Grekin. Sustained hypertension induced by orally administered nitro-L-arginine. Hypertension Dallas 21: 359-363, 1993.
9. DeClue, J. W., A. C. Guyton, A. W. Cowley, T. G. Coleman, R. A. Norman, and R. E. McCaa. Subpressor angiotensin infusion, renal sodium handling, and salt-induced hypertension in the dog. Circ. Res. 43: 503-512, 1978.
10. Dinerman, J. L., C. J. Lowenstein, and S. H. Snyder. Molecular mechanisms of nitric oxide regulation: potential relevance to cardiovascular disease. Circ. Res. 73: 217-222, 1993.
11. Fujihara, C. K., S. M. Michellazzo, G. DeNucci, and R. Zatz. Sodium excess aggravates hypertension and renal parenchymal injury in rats with chronic nitric oxide inhibition. Am. J. Physiol. 266 (Renal Fluid Electrolyte Physiol 35): F697-F705, 1994.
12. Gorbea-Oppliger, V. J., M. G. Melaragno, G. S. Potter, R. L. Petit, and G. D. Fink. Time course of losartan blockade of angiotensin II hypertension versus blockade of angiotensin II fast pressor effects. J. Pharmacol. Exp. Ther. 271: 804-810, 1994.
13. Hu, L., R. D. Manning, and M. W. Brands. Long-term cardiovascular role of nitric oxide in conscious rats. Hypertension Dallas 23: 185-194, 1994.
14. Ignarro, L. J., G. M. Buga, K. S. Wood, R. E. Byrns, and G. Chaudhuri. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc. Natl. Acad. Sci. USA 84: 9265-9269, 1987.
15. Jover, B., A. Herizi, F. Ventre, M. Dupont, and A. Mimran. Sodium and angiotensin in hypertension induced by long-term nitric oxide blockade. Hypertension Dallas 21: 944-948, 1993.
16. Klabunde, R. E., R. L. Ritger, and M. C. Helgren. Cardiovascular actions of inhibitors of endothelium-derived relaxing factor (nitric oxide) formation/release in anesthetized dogs. Eur. J. Pharmacol. 199: 51-59, 1991.
17. Korner, P. I., J. A. Angus, A. Bobik, and G. L. Jennings. Amplifier function of resistance vessels and the left ventricle in hypertension. J. Hypertens. 9, Suppl. 2: S31-S41, 1991.
18. Lowenstein, C. J., J. L. Dinerman, and S. H. Snyder. Nitric oxide: a physiologic messenger. Ann. Intern. Med. 120: 227-237, 1994.
19. MacGregor, G. A., N. D. Markandu, J. Bayliss, J. E. Roulston, M. Squires, and J. J. Morton. Non-sulfhydryl-containing angiotensin-converting enzyme inhibitor (MK 421): evidence for a role of renin system in normotensive subjects. Br. Med. J. 283: 401-403, 1981.
20. Manning, R. D., and L. Hu. Nitric oxide regulates renal hemodynamics and urinary sodium excretion in dogs. Hypertension Dallas 23: 619-625, 1994.
21. Matsuoka, H., H. Nishida, G. Nomura, B. N. VanVliet, and H. Toshima. Hypertension induced by nitric oxide synthesis inhibition is renal nerve dependent. Hypertension 23: 971-975, 1994.
22. Melaragno, M. G., and G. D. Fink. Enhanced slow pressor effect of angiotensin II in two kidney, one clip rats. Hypertension Dallas 25: 288-293, 1995.
23. Mento, P. F., and B. M. Wilkes. Plasma angiotensins and blood pressure during converting enzyme inhibition. Hypertension Dallas 9, Suppl. III: III42-III48, 1987.
24. Morton, J. J., E. C. Beattie, A. Speirs, and F. Gulliver. Persistent hypertension following inhibition of nitric oxide formation in the young Wistar rat: role of renin and vascular hypertrophy. J. Hypertens. 11: 1083-1088, 1993.
25. Osborn, J., J. Collister, and B. Hornfeldt. Hypotensive actions of losartan in normal rats: role of the area postrema and endogenous angiotensin II (AII) (Abstract). Hypertension Dallas 26: 558, 1995.
26. Palmer, R. M. J., A. G. Ferrige, and S. Moncada. Nitric oxide accounts for the biological activity of endothelium-derived relaxing factor. Nature Lond. 327: 524-526, 1987.
27. Pollock, D. M., J. S. Polakowski, B. J. Divish, and T. J. Opgenorth. Angiotensin blockade reverses hypertension during long-term nitric oxide synthase inhibition. Hypertension Dallas 21: 660-666, 1993.
28. Rees, D. D., R. M. J. Palmer, and S. Moncada. Role of endothelium-derived relaxing factor in the regulation of blood pressure. Proc. Natl. Acad. Sci. USA 86: 3375-3378, 1989.
29. Ribeiro, M. O., E. Antunes, G. DeNucci, S. M. Lovisolo, and R. Zatz. Chronic inhibition of nitric oxide synthesis: a new model of arterial hypertension. Hypertension Dallas 20: 298-303, 1992.
30. Sander, M., P. G. Hansen, and R. G. Victor. Sympathetically mediated hypertension caused by chronic inhibition of nitric oxide. Hypertension Dallas 26: 691-695, 1995.
31. Wong, P. C., W. A. Price, A. T. Chiu, J. V. Duncia, D. J. Carini, R. R. Wexler, A. L. Johnson, and P. B. M. W. M. Timmermans. Nonpeptide angiotensin II receptor antagonists. IX. Antihypertensive activity in rats of DuP 753, an orally active antihypertensive agent. J. Pharmacol. Exp. Ther. 252: 726-732, 1991.
32. Zatz, R., and G. DeNucci. Effects of acute nitric oxide inhibition on rat glomerular microcirculation. Am. J. Physiol. 261 (Renal Fluid Electrolyte Physiol. 30): F360-F363, 1991.